A 32-year-old woman from rural India presents with progressive dyspnea on exertion and orthopnea for 6 months. On examination, she has an opening snap and a low-pitched diastolic murmur best heard at the apex with the patient in the left lateral decubitus position. Chest X-ray shows straightening of the left heart border and pulmonary congestion. Echocardiography confirms mitral stenosis with a mitral valve area of 1.2 cm² and normal left ventricular function. She is currently in sinus rhythm. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient has symptomatic mitral stenosis (MS) with a valve area of 1.2 cm² (moderate-to-severe stenosis) and is in NYHA functional class II–III (dyspnea on exertion and orthopnea). ## Management Algorithm for Symptomatic Mitral Stenosis ```mermaid flowchart TD A[Mitral Stenosis diagnosed]:::outcome --> B{Symptomatic?}:::decision B -->|No symptoms| C[Anticoagulation if AF present<br/>Endocarditis prophylaxis<br/>Regular follow-up]:::action B -->|Symptomatic| D{Valve area & gradient?}:::decision D -->|Severe stenosis<br/>MVA < 1.0 cm²| E[Refer for intervention<br/>Valvotomy or MVR]:::action D -->|Moderate stenosis<br/>MVA 1.0-1.5 cm²| F[Trial of medical therapy first]:::action F --> G{Response to therapy?}:::decision G -->|Good response| H[Continue medical management<br/>Repeat echo annually]:::action G -->|Persistent symptoms| I[Refer for valvotomy/MVR]:::action ``` ## Rationale for Medical Management First **Key Point:** In symptomatic MS with moderate stenosis (MVA 1.0–1.5 cm²), medical therapy is the first-line approach before considering intervention. **High-Yield:** The three pillars of medical management are: 1. **Diuretics** — reduce pulmonary congestion and preload 2. **Beta-blockers or rate-limiting calcium channel blockers** — slow ventricular rate, prolong diastolic filling time, reduce symptoms 3. **Anticoagulation** — prevent thromboembolism (especially if atrial fibrillation develops) **Clinical Pearl:** Beta-blockers are preferred over dihydropyridine calcium channel blockers in MS because they reduce heart rate and improve diastolic filling, whereas dihydropyridines cause reflex tachycardia and worsen symptoms. ## When to Refer for Intervention - **Severe stenosis** (MVA < 1.0 cm²) with any symptoms → immediate intervention - **Moderate stenosis** (MVA 1.0–1.5 cm²) with **persistent symptoms despite optimal medical therapy** → intervention - **Asymptomatic severe stenosis** with pulmonary hypertension or new-onset AF → consider intervention **Mnemonic: SEVERE MS NEEDS INTERVENTION — S (Severe MVA < 1.0), E (Escalating symptoms despite meds), V (Very high gradient), E (Escalating pulmonary hypertension)** ## Why Valvotomy Is Not Immediate Here Although this patient has moderate-to-severe stenosis, she has not yet been optimized on medical therapy. The guideline-recommended approach is to trial diuretics and beta-blockers first; if symptoms persist or worsen despite compliance, then refer for percutaneous mitral balloon valvotomy (PMBV) or surgical mitral valve replacement (MVR). [cite:Harrison 21e Ch 297]